NCT04362007 2026-02-25A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell LymphomaOtsuka Pharmaceutical Co., Ltd.Phase 1/2 Terminated8 enrolled 11 charts
NCT04155580 2024-08-02A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)Astex Pharmaceuticals, Inc.Phase 1 Terminated68 enrolled